drugset
drugset / Trial / NCT05056246

Study of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian Participants

NCT05056246 ↗

Phase 1 Completed 34 enrolled Amgen
RandomizedParallel-groupOpen-labelBasic science

Summary

The primary objective of this study is to evaluate the pharmacokinetics (PK) of AMG 133 after single subcutaneous (SC) administration in healthy Japanese and Caucasian participants.

Timeline

Start
2021-09-10
Primary completion
2022-04-08
Completion
2022-04-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Maridebart Cafraglutide Unknown — Subcutaneous

Indications

No indication recorded.